SCHEMBL1674701

SCHEMBL1674701

COc1[c]nccc1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2066927 0.81 NQO1 (0.34)
SCHEMBL197155 0.77 CA12 (0.35)
SCHEMBL2066408 0.77 TSHR (0.37)
SCHEMBL3431780 0.76
SCHEMBL3431812 0.76
SCHEMBL2066424 0.76
SCHEMBL3430889 0.76
SCHEMBL1965518 0.76
SCHEMBL14938523 0.75
SCHEMBL15823929 0.75 PDE10A (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48622-E1 Therapeutically active pyrazolo-pyrimidine derivatives UCB Biopharma SRL (BE) 2021-07-06 US claimed
EP-3157922-B1 PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2018-11-28 EP claimed
US-10087180-B2 Pyrazolo-pyridine derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2018-10-02 US claimed
US-10000497-B2 Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BY) 2018-06-19 US claimed
EP-2935269-B1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2018-04-11 EP claimed
US-9714248-B2 Therapeutically active pyrazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2017-07-25 US claimed
US-20170121324-A1 Pyrazolo-Pyridine Derivatives as Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2017-05-04 US claimed
US-20170121337-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2017-05-04 US claimed
EP-3157922-A1 PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2017-04-26 EP claimed
EP-3157924-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2017-04-26 EP claimed
WO-2015193167-A1 PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 WO claimed
WO-2015193169-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 WO claimed
EP-2935269-A1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB Biopharma SPRL (BE) 2015-10-28 EP claimed
WO-2014096423-A1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB PHARMA S.A. (BE) 2014-06-26 WO claimed
US-8436000-B2 Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-05-07 US claimed
EP-2307024-B1 SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2013-01-09 EP claimed
JP-2011529899-A 2011-12-15 JP claimed
US-20110124662-A1 Substituted Carbamate Derivatives as Modulators of Corticotropin-Releasing Factor Receptor Activity BRISTOL-MYERS SQUIBB COMPANY 2011-05-26 US claimed
EP-2307024-A1 SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2011-04-13 EP claimed
WO-2010014687-A1 SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-04 WO claimed